11.95

6.20% -0.79

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $11.95, with a volume of 329.45K. It is down -6.20% in the last 24 hours and up +28.36% over the past month. Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Previous Close:

$12.74

Open:

$12.74

24h Volume:

329.45K

Relative Volume:

0.51

Market Cap:

$674.80M

Revenue:

$8.78M

Net Income/Loss:

$-104.70M

P/E Ratio:

-5.0422

EPS:

-2.37

Net Cash Flow:

$-82.68M

1W Performance:

+4.09%

1M Performance:

+28.36%

6M Performance:

-12.84%

1Y Performance:

+175.35%

1-Day Range:

$11.93

$12.90

1-Week Range:

$11.03

$12.98

52-Week Range:

$4.09

$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

110

Twitter

@stoketx

Next Earnings Date

2024-11-05

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	11.98	674.80M	8.78M	-104.70M	-82.68M	-2.37
VRTX Vertex Pharmaceuticals Inc	474.04	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.08	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	652.89	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.69	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.71	28.75B	3.30B	-501.07M	1.03B	-2.1146

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

04:24 AM

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Price Target from Analysts - Armenian Reporter

04:24 AM

Feb 06, 2025